Lupin’s Amlodipine and Valsartan tablets are indicated for the treatment of hypertension and to lower blood pressure
Lupin announced that its US subsidiary, Lupin Pharmaceuticals Inc. (collectively Lupin) has launched its Amlodipine and Valsartan tablets, 5 mg/160 mg, 10 mg/160 mg, 5 mg/320 mg and 10 mg/320 mg, which are the AB rated generic equivalent of Novartis Pharmaceuticals Corporation’s Exforge tablets 5 mg/160 mg, 10 mg/160 mg, 5 mg/320 mg and 10 mg/320mg strengths.
Lupin had received final approval from the United States Food and Drug Administration (FDA) for the product.
Lupin’s Amlodipine and Valsartan tablets is the combination tablet of amlodipine, a dihydropyridine calcium channel blocker (DHP CCB) and Valsartan, an angiotensin II receptor blocker (ARB). Lupin’s Amlodipine and Valsartan tablets are indicated for the treatment of hypertension and to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
Exforge tablets had US sales of US$ 414.9 million (IMS MAT December, 2014).
Comments are closed.